Evidence map›Paper›PMID 39191488›Full record

ArticleLife science alliance2024

Identification of single-cell blasts in pediatric acute myeloid leukemia using an autoencoder.

Alice Driessen, Susanne Unger, An-Phi Nguyen, Rhonda E Ries, Soheil Meshinchi, Stefanie Kreutmair, Chiara Alberti, Pavel Sumazin, Richard Aplenc, Michele S Redell and 2 more

Abstract read
In one paragraph

Article in Life science alliance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alice DriessenData and AI Research, IBM Research Europe, Zürich, Switzerland.ORCID 0000-0002-8822-2606
Susanne UngerInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-6916-7544
An-Phi NguyenData and AI Research, IBM Research Europe, Zürich, Switzerland.
Rhonda E RiesFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Soheil MeshinchiFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Stefanie KreutmairInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Chiara AlbertiInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Pavel SumazinDepartment of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Richard AplencChildren's Hospital of Philadelphia, Philadelphia, PA, USA.
Michele S RedellTexas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX, USA.
Burkhard BecherInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland becher@immunology.uzh.ch.ORCID 0000-0002-1541-7867
María Rodríguez MartínezData and AI Research, IBM Research Europe, Zürich, Switzerland maria.rodriguezmartinez@yale.edu.ORCID 0000-0003-3766-4233

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
COG U24 Funding 2026-2027U24CA196173 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Mignon Lee-Cheun Loh, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$62.5M
European Research CouncilNCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA196173
6 · The paper itself

Abstract

Pediatric acute myeloid leukemia (AML) is an aggressive blood cancer with a poor prognosis and high relapse rate. Current challenges in the identification of immunotherapy targets arise from patient-specific blast immunophenotypes and their change during disease progression. To overcome this, we present a new computational research tool to rapidly identify malignant cells. We generated single-cell flow cytometry profiles of 21 pediatric AML patients with matched samples at diagnosis, remission, and relapse. We coupled a classifier to an autoencoder for anomaly detection and classified malignant blasts with 90% accuracy. Moreover, our method assigns a developmental stage to blasts at the single-cell level, improving current classification approaches based on differentiation of the dominant phenotype. We observed major immunophenotype and developmental stage alterations between diagnosis and relapse. Patients with KMT2A rearrangement had more profound changes in their blast immunophenotypes at relapse compared to patients with other molecular features. Our method provides new insights into the immunophenotypic composition of AML blasts in an unbiased fashion and can help to define immunotherapy targets that might improve personalized AML treatment.

Indexed as

ImmunophenotypingLeukemia, Myeloid, AcuteSingle-Cell AnalysisAdolescentChildChild, PreschoolComputational BiologyFemaleFlow CytometryHistone-Lysine N-MethyltransferaseHumansInfantMaleMyeloid-Lymphoid Leukemia ProteinPrognosisHistone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia Protein

Identifiers

PMID39191488
PMCPMC11358707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.